U.S. Markets close in 2 hrs 59 mins
  • S&P 500

    4,360.79
    +34.28 (+0.79%)
     
  • Dow 30

    34,205.04
    +44.26 (+0.13%)
     
  • Nasdaq

    13,537.71
    +184.93 (+1.38%)
     
  • Russell 2000

    1,933.27
    +1.98 (+0.10%)
     
  • Crude Oil

    86.98
    +0.37 (+0.43%)
     
  • Gold

    1,784.60
    -10.40 (-0.58%)
     
  • Silver

    22.22
    -0.46 (-2.03%)
     
  • EUR/USD

    1.1154
    +0.0007 (+0.0669%)
     
  • 10-Yr Bond

    1.7860
    -0.0210 (-1.16%)
     
  • Vix

    29.64
    -0.85 (-2.79%)
     
  • GBP/USD

    1.3389
    +0.0008 (+0.0602%)
     
  • USD/JPY

    115.2400
    -0.0620 (-0.0538%)
     
  • BTC-USD

    36,877.21
    +500.63 (+1.38%)
     
  • CMC Crypto 200

    839.61
    -2.85 (-0.34%)
     
  • FTSE 100

    7,466.07
    -88.24 (-1.17%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

Histogen to Report Third Quarter 2020 Earnings on November 12, 2020

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • HSTO

SAN DIEGO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the third quarter ended September 30, 2020 will be released after the close of market on Thursday, November 12, 2020.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President & CFO
Histogen Inc.
ir@histogen.com